← All organizations
Highest phase reached
Phase 4
First clinical trial
Sep 1, 1998Last known activity
Nov 30, 2025
Timeline
1960s
- Jan 1, 1964
Institut National de la Santé Et de la Recherche Médicale, France— Founded
Drugs by trial phase (201 distinct, 169 trials)
Phase 4 (16 own, 0 via acquisition)
Phase 3 (79 own, 0 via acquisition)
Phase 2 (68 own, 0 via acquisition)
Phase 1 (17 own, 0 via acquisition)
Other trials (21 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Airway Remodeling
- Apnea
- Arthritis
- Arthritis, Juvenile
- Asthma
- Atrial Fibrillation
- Atrophy
- Bacterial Infections
- Brain Injuries
- Breast Neoplasms
- Bronchiolitis
- Bronchopulmonary Dysplasia
- Candidiasis
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Cerebral Hemorrhage
- Chorioretinitis
- Chronic Pain
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Common Variable Immunodeficiency
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Coronaviridae Infections
- Coronavirus Infections
- Crohn Disease
- Cystic Fibrosis
- Cytomegalovirus Infections
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diarrhea
- Ductus Arteriosus, Patent
- Emergencies
- Endocrine System Diseases
- Endometrial Neoplasms
- Epilepsy
- Erectile Dysfunction
- Fibrosis
- Fibrous Dysplasia of Bone
- Glioblastoma
- Glucose Metabolism Disorders
- Glycogen Storage Disease
- Glycogen Storage Disease Type V
- Gonorrhea
- Heart Failure
- Hemiplegia
- Hemorrhage
- Hemorrhagic Fever, Ebola
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- HIV Infections
- Huntington Disease
- Hyperparathyroidism
- Hyperplasia
- Hypertension
- Hypoglycemia
- Hypotension
- Hypoxia
- Idiopathic Pulmonary Fibrosis
- Immunologic Deficiency Syndromes
- Impulsive Behavior
- Infarction
- Infections
- Inflammation
- Inflammatory Bowel Diseases
- Influenza, Human
- Insulin Resistance
- Intestinal Diseases
- Intracranial Hypertension
- Ischemia
- Kidney Failure, Chronic
- Leukodystrophy, Metachromatic
- Lichen Planus
- Lichen Planus, Oral
- Lupus Erythematosus, Systemic
- Major Depressive Disorder
- Malaria
- Malaria, Falciparum
- Melanoma
- Meningitis
- Mesothelioma
- Metabolic Diseases
- Metabolism, Inborn Errors
- Multiple System Atrophy
- Muscle Spasticity
- Muscle Weakness
- Myasthenia Gravis
Recent trials (50)
- NCT07054359CollaboratorN/ANov 30, 2025
- NCT06892951CollaboratorPhase 1/Phase 2Jun 30, 2025
- NCT07113106CollaboratorPhase 1/Phase 2Jun 18, 2025
- NCT06681402Lead sponsorPhase 1Jan 31, 2025
- NCT06930261Lead sponsorPhase 2Jan 14, 2025
- NCT06687993CollaboratorPhase 2Nov 30, 2024
- NCT06572761OfficialPhase 3Sep 30, 2024
- NCT06427421OfficialN/AJun 30, 2024
- NCT06139796CollaboratorPhase 1/Phase 2Jun 30, 2024
- NCT06446960Lead sponsorPhase 3Feb 12, 2024
- NCT06024421Study directorPhase 1Nov 30, 2023
- NCT06024421OfficialPhase 1Nov 30, 2023
- NCT06024421Lead sponsorPhase 1Nov 30, 2023
- NCT05513807CollaboratorPhase 3Nov 30, 2022
- NCT05545384CollaboratorPhase 2/Phase 3Nov 30, 2022
Details
- Founded
- Paris, FR Jan 1, 1964
- Last known activity
- Nov 30, 2025
Notes
Alternative name: French National Institute of Health and Medical Research